MeiraGTx Holdings (MGTX) Net Income towards Common Stockholders (2017 - 2025)

MeiraGTx Holdings (MGTX) posted Net Income towards Common Stockholders of $15.1 million for Q4 2025, up 129.87% on a QoQ basis from -$50.5 million in Q3 2025, and up 138.3% year-over-year from $6.3 million in Q4 2024.

MeiraGTx Holdings (MGTX) Net Income towards Common Stockholders (2017 - 2025) Analysis & Trends

MeiraGTx Holdings' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at $15.1 million for Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 138.3% year-over-year to $15.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$114.2 million (up 22.73% YoY) and the FY2025 annual result came in at -$114.2 million, up 22.73% from the prior year.
  • Net Income towards Common Stockholders was $15.1 million for Q4 2025 at MeiraGTx Holdings, up from -$50.5 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $20.2 million in Q4 2023 and bottomed at -$50.5 million in Q3 2025.
  • A 5-year average of -$27.8 million and a median of -$30.7 million in 2022 frame the typical range for Net Income towards Common Stockholders.
  • Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders slumped 303.37% — and 2023, when it jumped 174.01%.
  • MeiraGTx Holdings' Net Income towards Common Stockholders stood at -$9.9 million in 2021, then slumped by 175.55% to -$27.3 million in 2022, then soared by 174.01% to $20.2 million in 2023, then plunged by 294.9% to -$39.4 million in 2024, then jumped by 138.3% to $15.1 million in 2025.
  • Business Quant data shows MGTX's Net Income towards Common Stockholders at $15.1 million in Q4 2025, -$50.5 million in Q3 2025, and -$38.8 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,831.58 Bn 66,831.30 Bn - -625.73
2 Nanobiotix 1,916.61 Bn 1,916.55 Bn - -
3 Akari Therapeutics 976.78 Bn 976.78 Bn - -14.46 Mn
4 BeOne Medicines 471.48 Bn 466.69 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.78 Bn 114.53 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.87 Bn 61.12 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 63.06 Bn 63.06 Bn - -0.68
8 Argenx Se 55.78 Bn 50.60 Bn 1.41 Bn 472.00 Mn
9 Alnylam Pharmaceuticals 37.54 Bn 34.53 Bn 959.66 Mn 205.99 Mn
10 MeiraGTx Holdings 1.00 Bn 935.42 Mn - 15.09 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 15.09 Mn
Sep 30, 2025 -50.51 Mn
Jun 30, 2025 -38.80 Mn
Mar 31, 2025 -39.98 Mn
Dec 31, 2024 -39.40 Mn
Sep 30, 2024 -39.33 Mn
Jun 30, 2024 -48.62 Mn
Mar 31, 2024 -20.44 Mn
Dec 31, 2023 20.22 Mn
Sep 30, 2023 -44.30 Mn
Jun 30, 2023 -29.58 Mn
Mar 31, 2023 -30.36 Mn
Dec 31, 2022 -27.31 Mn
Sep 30, 2022 -37.28 Mn
Jun 30, 2022 -33.97 Mn
Mar 31, 2022 -31.05 Mn
Dec 31, 2021 -9.91 Mn
Sep 30, 2021 -25.95 Mn
Jun 30, 2021 -20.09 Mn
Mar 31, 2021 -23.62 Mn